CytoSorbents Corporation (CTSO)

[orangecat]

I'm not sure if this is a soft bash or your math is just off. A share price of $30 puts the market cap a just under 1 billion. There are development stage biotechs with market caps near this level.

Dr. Chan has cited many time that the potential market for Critical care in Germany alone could be in the 400 M to 1.2 B range. In that estimate he mentions that there are 400 hospitals in Germany with 400+ beds and he also cites 1-3 million in sales per hospital. Recently he also mentions they have reached there first 1 M/year hospital in Germany and that there are other approaching this level. So his estimate are not out of the realm of possibility. Now multiply these numbers by all the other countries where sales will be ramping up over the next few years. Then add in the other indications and a US FDA approval for cardiac surgery. Then add in bringing Hemodefend and the potassium adsorber to market, etc. Don't forget Contrasorb, Drugsorb, Betasorb and of course Cytosorb XL.

If everything falls in to place, earnings over 1 B per year in the next 3-4 years could be a reality. A PE ratio of 20 would then put the market cap at 20 B and your share price at $600. Of course there will likely be more dilution for further studies and manufacturing expansion. But you get the idea of where this company could go.